A-2B530 is under clinical development by A2 Biotherapeutics and currently in Phase II for Solid Tumor. According to GlobalData, Phase II drugs for Solid Tumor have a 21% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how A-2B530’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
A-2B530 is under development for the treatment of solid tumor including metastatic colorectal cancer, lung cancer and pancreatic cancer. The therapy constitutes of genetically manipulated autologous Tmod (T-cell module) T cells which express chimeric antigen receptors (CAR) targeting cells expressing tumor antigens. It acts by targeting CEA and HLA-A02 (HLA-A2). It is administered through intravenous route.
A2 Biotherapeutics overview
A2 Biotherapeutics (A2) is a biotechnology company, focused on cell therapy, that aspires to beat cancer via tumor-specific targeting. It is headquartered in Agoura Hills, California, the US.
For a complete picture of A-2B530’s drug-specific PTSR and LoA scores, buy the report here.